Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease
Recruiting · NCT06397677 · Observational (researchers observe without assigning treatment) · Lead sponsor: University of Colorado, Denver
View the official record on ClinicalTrials.gov →Interventions studied
Information Collected as Standard of CareResearch Testing PerformedResearch Testing Performed (Laboratory)
What this trial is about
A study to identify patients with Rheumatoid Arthritis - Associated Interstitial Lung Disease (RA-ILD) that are at the highest risk for progression. The goal of the investigators is to recruit a group of patients with RA-ILD and collect information to help us understand more about disease progression. The investigators will do this using a combination of clinical, radiologic, and biologic features.
Who can take part
Age range
18 Years to 90 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Multidisciplinary diagnosis of RA-ILD based on the 2010 American College of Rheumatology criteria
- 18 years of age or older
Exclusion criteria
- Prior medication treatment specifically for RA-ILD
- Inability to give informed consent
- Pregnant women
Where it is running
4 locations listed across 4 US states.
- University of California San Francisco - San Francisco, California, United States
- University of Colorado Denver - Aurora, Colorado, United States
- University of Kansas - Kansas City, Kansas, United States
- University of Michigan - Ann Arbor, Michigan, United States